GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Gross Profit

Reshape Lifesciences (STU:24O0) Gross Profit : €5.07 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Gross Profit?

Reshape Lifesciences's gross profit for the three months ended in Mar. 2024 was €1.07 Mil. Reshape Lifesciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €5.07 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Reshape Lifesciences's gross profit for the three months ended in Mar. 2024 was €1.07 Mil. Reshape Lifesciences's Revenue for the three months ended in Mar. 2024 was €1.79 Mil. Therefore, Reshape Lifesciences's Gross Margin % for the quarter that ended in Mar. 2024 was 59.96%.

Reshape Lifesciences had a gross margin of 59.96% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Reshape Lifesciences was 72.98%. The lowest was 41.48%. And the median was 60.52%.

Warning Sign:

Reshape Lifesciences Inc gross margin has been in long-term decline. The average rate of decline per year is -1.8%.


Reshape Lifesciences Gross Profit Historical Data

The historical data trend for Reshape Lifesciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Gross Profit Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.38 5.15 7.39 6.42 5.09

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.10 1.21 1.69 1.07

Competitive Comparison of Reshape Lifesciences's Gross Profit

For the Medical Devices subindustry, Reshape Lifesciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Gross Profit falls into.



Reshape Lifesciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Reshape Lifesciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=7.958 - 2.87
=5.09

Reshape Lifesciences's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1.788 - 0.716
=1.07

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.07 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Reshape Lifesciences's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1.07 / 1.788
=59.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Reshape Lifesciences  (STU:24O0) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Reshape Lifesciences had a gross margin of 59.96% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Reshape Lifesciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines